Homepage > Company > Media > Pharma News > 2021 > U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir

U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir

(Reuters) - The U.S. health regulator expanded the emergency use authorization for Eli Lilly’s COVID-19 drug baricitinib, saying it could now be used without taking Gilead’s drug remdesivir along with it, Lilly said on Thursday.

Baricitinib (INCB028050) | ≥99%(HPLC) | Selleck | JAK inhibitor — **Baricitinib**

In November, the U.S. Food and Drug Administration (FDA) approved Lilly and Incyte’s arthritis drug, baricitinib, in combination with remdesivir, to treat COVID-19 patients.

“Based on the increasing body of evidence, we are confident in the potential of baricitinib as an important treatment for the hospitalized COVID-19 patient population requiring supplemental oxygen,” Lilly said on Thursday.

FDA’s expanded use for baricitinib was based on results from a trial done by the company in April.

The trial did not meet the main goal of preventing progression to ventilator use in hospitalized COVID-19 patients. However, the study showed baricitinib-treated patients were less likely than those receiving standard of care to progress to ventilator use or death.

The study enrolled 1,525 hospitalized COVID-19 patients who received either baricitinib or a placebo, along with the standard of care, which included corticosteroids and remdesivir.

JULY 29, 2021

https://www.reuters.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...